Incyte (INCY) Other Operating Expenses (2012 - 2026)
Incyte's (INCY) quarterly Other Operating Expenses came in at $127.6 million in Q1 2026, up 50.51% YoY from $84.8 million in Q1 2025, and down 47.34% on a QoQ basis from $242.3 million in Q2 2025.
Incyte (INCY) Other Operating Expenses (2012 - 2026) Analysis & Trends
Incyte (INCY) has 15 years of Other Operating Expenses data on file, last reported at $127.6 million in Q1 2026.
- Quarterly Other Operating Expenses rose 50.51% year-over-year to $127.6 million in Q1 2026, while the trailing twelve-month figure through Jun 2026 was $127.6 million (down 60.99% YoY) and the FY2025 annual result came in at $242.3 million, changed N/A from the prior year.
- Other Operating Expenses slipped to $127.6 million in Q1 2026, from $242.3 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $242.3 million in Q2 2025 to a low of $34.5 million in Q3 2022.
- A 5-year average of $86.1 million and a median of $68.9 million in 2023 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2022 — Other Operating Expenses slumped 33.64% — and 2023, when it jumped 76.2%.
- Tracing INCY's Other Operating Expenses over 5 years: stood at $82.4 million in 2022, then rose by 13.24% to $93.3 million in 2023, then sank by 36.28% to $59.5 million in 2024, then surged by 307.32% to $242.3 million in 2025, then plunged by 47.34% to $127.6 million in 2026.
- The last three Other Operating Expenses figures came in at $127.6 million (Q1 2026), $242.3 million (Q2 2025), and $84.8 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 127.57 Mn |
| Jun 30, 2025 | 242.25 Mn |
| Mar 31, 2025 | 84.76 Mn |
| Mar 31, 2024 | 59.48 Mn |
| Dec 31, 2023 | 93.34 Mn |
| Sep 30, 2023 | 60.72 Mn |
| Jun 30, 2023 | 76.15 Mn |
| Mar 31, 2023 | 61.66 Mn |
| Dec 31, 2022 | 82.43 Mn |
| Sep 30, 2022 | 34.46 Mn |
| Jun 30, 2022 | 56.49 Mn |
| Mar 31, 2022 | 53.74 Mn |
| Dec 31, 2021 | 53.09 Mn |
| Sep 30, 2021 | 51.93 Mn |
| Jun 30, 2021 | 52.50 Mn |
| Mar 31, 2021 | 45.23 Mn |
| Dec 31, 2020 | 52.35 Mn |
| Sep 30, 2020 | 56.42 Mn |
| Jun 30, 2020 | 52.67 Mn |
| Mar 31, 2020 | 36.08 Mn |